- Report
- September 2022
- 242 Pages
Global
From €2275EUR$2,499USD£1,932GBP
€3249EUR$3,570USD£2,760GBP
- Report
- July 2022
- 274 Pages
Global
From €2351EUR$2,583USD£1,997GBP
€3359EUR$3,690USD£2,853GBP
- Report
- June 2022
- 230 Pages
Global
From €2202EUR$2,419USD£1,870GBP
€3146EUR$3,456USD£2,672GBP
The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications.
The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more